Clinical trial · Interventional
Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to see if people can produce ketones in their blood with the modified Atkins diet. Modified Atkins diet is a diet that produces ketones in your blood by restricting carbohydrates to \<20 grams per day. Ketones are substances that are produced in the blood when fat is being broken down. Ketones may help radiation work better and may starve your tumor because it is thought that some brain tumors can not use ketones to grow and can only use sugar or glucose to grow.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Modified Atkins Ketogenic Diet | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Modified Atkins Ketogenic Diet
- description
- Modified Atkins Ketogenic Diet in combination with Temodar and Radiation
- interventionNames
- Other: Modified Atkins Ketogenic Diet
Primary outcomes (1)
- measure
- Number of Participants With Ketosis
- timeFrame
- 6 weeks
- description
- Ketosis measured by serum beta-hydroxybuterate. Ketosis is defined as having serum beta-hydroxybuterate (BHB) at \> 0.05 mM. Participants' BHB levels were assessed at 6 weeks after starting the study. The number of participants who had BHB at \> 0.05 mM were considered to have entered into ketosis. 9 of 9 participants met this criteria.
Secondary outcomes (2)
- measure
- Number of Participants With Progression Free Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed primary malignant glioma, Grade III or IV * No uncontrolled infection or other active malignancy or chronic systemic immune therapy. * ECOG performance status \< 3. * Life expectancy \> three months. * Adequate labs Exclusion Criteria: * Diagnosis of genetic disorder of fat metabolism. * Type 2 diabetes diagnosed with a hemoglobin A1C \> 6.4 * Allergic to dairy or lactose intolerance
References
Publications (0)
Data not yet available